Composición farmacéutica de liberación sostenida para el tratamiento y prevención de enfermedades oculares

• Main Authors: KOMORIYA, Satoshi, NAKAGAMI, Yasuhiro, MURAKAMI, Yoko, IIZUKA, Mayumi, MINAMI, Masako, HATANO, Emiko, OHNUKI, Takashi, IWASAKI, Masaru, KASUYA, Yuji, ONO, Yasunori, SAKAMOTO, Atsunobu, MASUDA, Kayoko, YOSHIDA, Kazuhiro, INOUE, Tatsuya
• Format: Patent
• Language: Spanish
• Published: 03.07.2020
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; ENZYMOLOGY; FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIREDCHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERSFROM A RACEMIC MIXTURE; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MUTATION OR GENETIC ENGINEERING; ORGANIC CHEMISTRY; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; SPIRITS; STEROIDS; VINEGAR; WINE

Un derivado terpenoide representado por la siguiente fórmula (I): **(Ver fórmula)** The present invention relates to a terpenoid derivative that has the ability to activate the Keap1/Nrf2/ARE signaling pathway and is excellent in anti-inflammatory action and cytoprotective action, and a sustained-release pharmaceutical composition effective for the treatment and prevention of a posterior eye disease caused by oxidative stress, comprising the terpenoid derivative as an active ingredient. The present invention provides a local administration-type sustained-release pharmaceutical composition for the treatment or prevention of a posterior eye disease, comprising the terpenoid derivative of the present invention as an active ingredient, wherein the sustained-release pharmaceutical composition maintains a pharmacological action thereof for 1 week or longer by the sustained release of the terpenoid derivative under physiological conditions and has a base material administrable to the vitreous body and a form administrable to the vitreous body